Abstract |
Thirty-seven eligible patients with advanced non-Hodgkin's lymphoma of low-grade, T-cell intermediate- and high-grade histology were treated with pentostatin (2'-deoxycoformycin, dCF) 4mg/m2 i.v. weekly for 3 weeks and then every 14 days to be followed after 3 doses by the same dosage every 4 weeks until maximum response or progression. Only patients with no more than two chemotherapy regimens were entered in this trial. All patients had measurable disease, performance status of 1,0 and 2 and adequate bone marrow, renal and liver function. Five of 37 eligible patients experienced a partial response of 8 months' median duration (range 7-12). The response rate was 17% in low-grade, 8% in T-cell intermediate- and high-grade and 14% in cutaneous T cell lymphoma. The only eligible patient with Hodgkin's disease underwent progression while on treatment. One case presented with grade 3 leukopenia and another one died of septicaemia, possibly treatment-related. Elevated but reversible creatinine levels were observed in 13% of patients and conjunctivitis in 7%. The toxicity of dCF at this low-dose schedule was acceptable, but the therapeutic activity in pretreated patients with low-grade, T-cell intermediate- and high-grade and cutaneous T-cell lymphomas was limited.
|
Authors | S Monfardini, R Sorio, F Cavalli, T H Cerny, M Van Glabbeke, S Kaye, J F Smyth |
Journal | Oncology
(Oncology)
1996 Mar-Apr
Vol. 53
Issue 2
Pg. 163-8
ISSN: 0030-2414 [Print] Switzerland |
PMID | 8604244
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study)
|
Chemical References |
- Enzyme Inhibitors
- Pentostatin
|
Topics |
- Adult
- Aged
- Combined Modality Therapy
- Enzyme Inhibitors
(administration & dosage, adverse effects)
- Female
- Hodgkin Disease
(drug therapy)
- Humans
- Lymphoma, T-Cell
(drug therapy, radiotherapy)
- Lymphoma, T-Cell, Cutaneous
(drug therapy, radiotherapy)
- Male
- Middle Aged
- Pentostatin
(administration & dosage, adverse effects)
- Remission Induction
- Skin Neoplasms
(drug therapy, radiotherapy)
- Treatment Outcome
|